FY2026 Earnings Estimate for ZVRA Issued By William Blair

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities research analysts at William Blair issued their FY2026 EPS estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, November 13th. William Blair analyst S. Corwin forecasts that the company will post earnings of $0.54 per share for the year. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.63) per share.

A number of other equities research analysts have also issued reports on the stock. JMP Securities began coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective for the company. Roth Mkm raised their price target on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group reduced their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Monday, September 30th. Finally, Guggenheim began coverage on Zevra Therapeutics in a research report on Monday, October 7th. They issued a “buy” rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $21.00.

Zevra Therapeutics Stock Down 4.5 %

Shares of ZVRA opened at $8.62 on Friday. Zevra Therapeutics has a 52-week low of $4.18 and a 52-week high of $9.21. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The stock has a fifty day simple moving average of $8.03 and a two-hundred day simple moving average of $6.49. The company has a market capitalization of $453.57 million, a PE ratio of -4.38 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Zevra Therapeutics had a negative return on equity of 177.96% and a negative net margin of 342.63%. The company had revenue of $4.45 million for the quarter, compared to analyst estimates of $4.08 million. During the same period last year, the firm posted ($0.15) EPS.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock valued at $16,054,000 after buying an additional 2,312,384 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after acquiring an additional 58,866 shares during the period. State Street Corp grew its position in Zevra Therapeutics by 7.4% in the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares in the last quarter. Stonepine Capital Management LLC purchased a new stake in Zevra Therapeutics during the third quarter worth about $4,858,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Zevra Therapeutics during the third quarter worth about $3,644,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.